Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb:46:80-84.
doi: 10.1016/j.canep.2016.12.006. Epub 2017 Jan 2.

Proton pump inhibitors on pancreatic cancer risk and survival

Malcolm D Kearns  1 , Ben Boursi  2 , Yu-Xiao Yang  3
Affiliations

Proton pump inhibitors on pancreatic cancer risk and survival

Malcolm D Kearns et al. Cancer Epidemiol. 2017 Feb.

Abstract

Background: Hypergastrinemia may promote the development and progression of pancreatic cancer. Proton pump inhibitor (PPI) therapy is known to cause hypergastrinemia. We sought to determine the association between PPI therapy and the risk of developing pancreatic cancer as well as survival following pancreatic cancer diagnosis.

Methods: We conducted a nested case-control study and a retrospective cohort study in The Health Improvement Network (THIN), a medical records database representative of the UK population. In the case-control study, each patient with incident pancreatic cancer was matched with up to four controls based on age, sex, practice site and both duration and calendar time of follow-up using incidence density sampling. The odds ratios (ORs) and 95% confidence intervals (CIs) for pancreatic cancer risk associated with PPI use were estimated using multivariable conditional logistic regression. The retrospective cohort study compared the survival of pancreatic cancer patients according to their PPI exposure at the time of diagnosis. The effect of PPI use on pancreatic cancer survival was assessed using a multivariable Cox regression analysis.

Results: The case-control study included 4113 cases and 16,072 matched controls. PPI use was more prevalent in cases than controls (53% vs. 26% active users). Adjusting for diabetes, smoking, alcohol use and BMI, PPI users including both former users and active users with longer cumulative PPI use had a higher risk of pancreatic cancer compared to non-users. When assessing survival following pancreatic cancer diagnosis, only short-term, active users had a modest decrease in survival.

Conclusions: Long-term PPI therapy may be associated with pancreatic cancer risk. While PPI users recently started on treatment had a slightly worse survival, this result likely is from reverse causation.

Keywords: Pancreatic cancer; Proton pump inhibitors; Risk; Survival.

PubMed Disclaimer

Conflict of interest statement

none

References

    1. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest. 1996;98(9):2120–2128. - PMC - PubMed
    1. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121(3):161–167. - PubMed
    1. Lamberts R, Creutzfeldt W, Stockmann F, et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988;39(2):126–135. - PubMed
    1. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99(3):621–628. - PubMed
    1. Hakanson R, Bottcher G, Sundler F, et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion. 1986;35(Suppl 1):23–41. - PubMed

Substances